Floatz logo

lp-108

Relapse Leukemia

Newave Pharmaceutical IncPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

125 Active assets in the Relapse Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
ASPARAGINASE
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB
Idarubicine
Affiliated Hospital of Nantong University
Phase 3BB
Daunorubicin
Richard Stone, MD
Phase 3BB

View all 50 →

Same molecule, other indications

lp-108 is also rated in:

chronic myelomonocytic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →
acute lymphoblastic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →
AML/MDSDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →